Newsletter

Int. Rev. Allergol. Clin. Immunol. Family Med., 2015, XXI/1: 021-024 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2015, XXI/1: 021-024

Title: Features of an ideal inhaler in testing a new inhaler device 

Authors: Płusa T, Bijoś P

More details

04-01-2015

30,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN ENGLISH.

Features of an ideal inhaler in testing a new inhaler device


Płusa T1, Bijoś P2.

1Military Institute of Medicine in Warsaw, Poland, Central Clinical Hospital of the Ministry of National Defense, Department of Internal Medicine, Pneumonology and Allergology; 2Medical Division, TEVA Pharmaceuticals Polska Sp. z o.o., Warsaw, Poland

Int. Rev. Allergol. Clin. Immunol. Family Med., 2015; Vol. 21, No. 1, 21

It is well known that a inhaler with greater ease of use should require less effort to teach patients how to use it and improve their compliance and therapy results. DuoResp Spiromax is a recently developed dry powder inhaler designed for maximum ease of use.
The aim of study
was to obtain opinions on the new DuoResp Spiromax device among asthma/COPD patients and healthcare professionals (HCPs) and to compare this inhaler with a currently used Turbohaler or Accuhaler.
Material and methods
. The study was performed in 80 patients with asthma or COPD in 9 European countries. In all patients qualitative face-to-face 261 interviews were performed. The second part of the study was focused on healthcare professionals (HCPs) including general practitioners and nurses – 20 per country (21 in Germany). The 181 interviews with HCPs were performed. The respondents’ evaluation of the DuoResp Spiromax took place on the basis of having seen a demonstration video, having had an opportunity to try the empty device and in case of HCPs additionally on having read the product profile of the Spiromax. The study was conducted by the Health division of GfK SE, Germany, which is a global independent market research company and was sponsored by TEVA Pharmaceuticals Europe B.V..
Results
. Almost three-quarters of patients (74%) said that the new device comes closer to their perception of an ideal inhaler. 76% of patients handled the new device correctly without receiving any instruction. The main reasons for considering the new device as better than the currently used device were: automatic priming mechanism in one step by simply opening the cover; better loading mechanism; and better dose counter. More than three-quarters of HCPs (77%) said that the new device comes closer to their perception of an ideal inhaler. HCPs consider that the ideal inhaler should be easy to handle; provide confirmation of successful inhalation; be convenient; have an ergonomic size and shape.
Conclusions
. Most asthma/COPD patients and HCPs regard the new Spiromax as preferable to their current device (Turbohaler). Main reasons for considering Spiromax as being unique are as follows: automatic priming mechanism in one step by simply opening the cover, higher efficacy, safety and compliance (easier to use, better loading mechanism with minimal risk of errors, better dose counter, more ergonomic shape)

Key words: spiromax, asthma, COPD, patients, HCPs